Genetic markers for response to chemo-radiation in rectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how your genes and radiation-related factors affect how well rectal cancer responds to chemo and radiation given before surgery. The goal is to help personalize treatment and predict outcomes for people with locally advanced rectal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have rectal cancer that is locally advanced, meaning it is large or deep (stage T3 or T4), but has not spread to other organs.
- Your doctors believe the cancer can be surgically removed.
- You are generally healthy enough to do normal daily activities (performance status 0-2).
- Your liver, kidneys, and bone marrow are working normally (checked with blood tests).
- You are scheduled to receive chemotherapy with radiation before surgery (neoadjuvant treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
This study looks at whether a genetic test on a small sample of your tumor can predict how well you will respond to chemotherapy and radiation before surgery. This might help doctors choose the best treatment for you.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests whether checking for tumor DNA in your blood after surgery can help decide if you need additional chemotherapy. If the test finds cancer DNA, you may get chemo to lower the risk of the cancer coming back.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.